AlphAIAlphAI — Financial news for AI agents
zacks.com$LQDA

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

Original reporting
zacks.com
Published Nov 11, 2026, 6:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 6:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales — source image
Source · zacks.com
Decision brief

The 30-second read

$LQDANeutralMed
01

Why it matters

The earnings beat and revenue surprise suggest strong product adoption, while the settlement introduces cash outflow risk.

02

Market read

Liquidia's results could influence biotech peer valuations and investor sentiment toward settlement risk.

03

What to watch

Future cash burn from pipeline R&D and potential additional legal exposures may not be fully priced in.

Relevance 7/10Novelty 8/10Timing: after-hours reaction

Background

Liquidia's Q3 results highlight rapid commercial uptake of Yutrepia and a significant one-time litigation settlement.

Company-level read

Ticker impact

$LQDANeutralHigh confidence
Context

Liquidia reported Q3 earnings beat and revenue beat, disclosed a $380.7M settlement, and the stock rose 7.37% after the announcement.

Expected impact

mixed pressure with potential modest upside as the beat may outweigh settlement concerns

Evidence & confidence

Strong revenue growth and EPS beat drive buying interest, while the settlement liability could limit gains.

Market effects

Sector

Biotech sector may see increased scrutiny on settlement risks but overall earnings strength could boost peer valuations.

Regional

U.S. biotech stocks may experience modest rally following the earnings beat.

Global

Limited to investors focused on U.S. biotech and specialty pharma.

Counterpoint

What could challenge this read

The settlement payment could weigh on cash flow, making the stock vulnerable to a pullback despite the earnings beat.

Key entities

  • Company
    Liquidia Corporation

    Biopharma company developing inhaled treprostinil therapies.

  • Company
    United Therapeutics

    Counterparty in the litigation settlement.

Read at source← All news

StoryLiquidia reports Q3 2026 loss after $389.7M settlement with United Therapeutics

Also covered by

4 outlets

Related articles

$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

investing.com
$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

finance.yahoo.com
$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.

finance.yahoo.com
$LQDAMed

BTIG raises Liquidia stock price target to $87 on strong demand

BTIG raised its price target for Liquidia Technologies (LQDA) to $87 from $70, citing strong demand for Yutrepia and increased 2027 EPS estimates. LQDA's Q3 revenue beat expectations at $225.3M, with Yutrepia sales up 31%, though GAAP EPS loss was $2.64 due to a $389.7M settlement charge. Jefferies also raised its target to $62, maintaining a Buy rating.

investing.com